NEW YORK – Guardant Health and ConcertAI said Thursday that they have entered a collaboration to provide biopharmaceutical companies with access to a multimodal real-world database that integrates comprehensive electronic medical record data with both genomic and epigenomic tumor profiling information.
The companies said that the joint offering provides added clinical context from ConcertAI's national database of 5.5 million clinical records to Guardant's extensive genomic resources. The aim is to supply biopharma collaborators with a tool to better interpret disease biology and identify drivers of tumor evolution and intrinsic or acquired resistance mechanisms, accelerating the design of new clinical trials and targeted therapies.
"Realizing the potential of precision medicine requires a comprehensive, multidimensional understanding of the tumor, the clinical environment, and the patient’s response to therapy," Guardant co-CEO Helmy Eltoukhy said in a statement.
The companies aim to distinguish the integrated offering from similar products with the inclusion of methylation data from biomarker tests run on the Guardant Infinity smart liquid biopsy platform, as well as genomic data from both molecular profiling in late-stage cancers and residual disease and recurrence monitoring in early-stage tumors.
Financial terms of the agreement were not disclosed.